Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.52EUR
19 Oct 2018
Change (% chg)

€-0.02 (-0.56%)
Prev Close
€3.54
Open
€3.50
Day's High
€3.53
Day's Low
€3.45
Volume
67,746
Avg. Vol
91,674
52-wk High
€4.19
52-wk Low
€2.64

Latest Key Developments (Source: Significant Developments)

Valneva Announces FDA Approval Of Accelerated IXIARO Vaccination Schedule
Friday, 5 Oct 2018 

Oct 5 (Reuters) - VALNEVA SE ::VALNEVA ANNOUNCES FDA APPROVAL OF ACCELERATED IXIARO VACCINATION SCHEDULE.FDA APPROVED ALTERNATE IXIARO IMMUNIZATION SCHEDULE OF 2 DOSES ADMINISTERED 7 DAYS APART FOR ADULT TRAVELERS AGED 18-65 YRS OLD.  Full Article

Oddo BHF Says Valneva Placement Priced At 3.75 Euros
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - ODDO BHF::VALNEVA PLACEMENT : SIZE INCREASED FROM 40M€ TO 50M€ THANKS TO VERY STRONG TRACTION, ESPECIALLY FROM USA .VALNEVA PLACEMENT : PRICING SET AT 3.75€ REPRESENTING 2.6% DISCOUNT VERSUS 3 DAYS VWAP.  Full Article

Valneva Reports EBITDA of 5.8 Million Euros In H1
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - VALNEVA SE ::REG-VALNEVA DELIVERS STRONG IXIARO® SALES GROWTH AND REPORTS FURTHER PROGRESS ON KEY RESEARCH AND DEVELOPMENT PROGRAMS IN H1.PRODUCT SALES OF EUR 53.5 MILLION IN H1 2018, REPRESENTING 11.4% YEAR ON YEAR.STRONG IXIARO(® )SALES REVENUE GROWTH OF OVER 19% DRIVEN BY US PRIVATE MARKET.TOTAL REVENUES WERE EUR 59.0 MILLION IN H1 2018 (VERSUS. EUR 53.9 MILLION IN H1 2017).EBITDA OF EUR 5.8 MILLION IN H1 2018, IN LINE WITH COMPANY 2018 GUIDANCE OF EUR 5.0 MILLION TO EUR 10.0 MILLION.PHASE 2 PREPARATION ACTIVITIES ONGOING FOR COMPANY'S LYME VACCINE CANDIDATE EXPECTED TO ENTER PHASE 2 AT END OF 2018.RECRUITMENT COMPLETED FOR PHASE 1 STUDY OF COMPANY'S CHIKUNGUNYA VACCINE CANDIDATE. RESULTS EXPECTED EARLY 2019.RECRUITMENT COMPLETED FOR PHASE 1 STUDY OF COMPANY'S ZIKA VACCINE CANDIDATE. RESULTS EXPECTED AT END OF 2018 OR EARLY 2019.H1 NET LOSS EUR 0.2 MILLION VERSUS LOSS OF EUR 4.4 MILLION YEAR AGO.  Full Article

Valneva Announces Update For Lyme Disease Vaccine Candidate VLA15
Monday, 2 Jul 2018 

July 2 (Reuters) - VALNEVA SE ::ANNOUNCED TODAY FURTHER UPDATE FOR ITS LYME DISEASE VACCINE CANDIDATE, VLA15.SUCCESSFULLY CONCLUDED END OF PHASE 1 PROCESS FOR THIS CANDIDATE WITH FOOD AND DRUG ADMINISTRATION (FDA) AND HAS OBTAINED ALIGNMENT WITH REGARD TO ITS PHASE 2 STRATEGY.HAS OBTAINED ALIGNMENT WITH REGARD TO ITS PHASE 2 STRATEGY.NOW FINALIZING DETAILED PHASE 2 PROTOCOL AND, SUBJECT TO REQUISITE REGULATORY APPROVALS.EXPECTS TO ENTER PHASE 2 CLINICAL DEVELOPMENT BY END OF 2018.WILL PROVIDE A FULL UPDATE ON ITS LYME PROGRAM DURING PUBLICATION OF ITS H1 RESULTS ON AUGUST 2, 2018.  Full Article

Valneva Q1 EBITDA Up At 4.9 Million Euros
Thursday, 17 May 2018 

May 17 (Reuters) - Valneva SE ::Q1 EBITDA OF €4.9 MILLION IN Q1 2018 (VERSUS. €3.4 MILLION IN Q1 2017).Q1 TOTAL REVENUES EUR 32.1 MILLION VERSUS EUR 28.4 MILLION YEAR AGO.Q1 NET PROFIT EUR 1.5 MILLION VERSUS LOSS OF EUR 1.7 MILLION YEAR AGO.  Full Article

Valneva Expands Its Commercial Operations And Establishes US Infrastructure
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - VALNEVA SE ::REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE.  Full Article

Valneva 9M EBITDA increases to 12.3 million euros
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - VALNEVA SE ::TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​.POSITIVE OPERATING CASH FLOW OF €18.2 MILLION IN THE FIRST NINE MONTHS OF 2017.9M EBITDA OF EUR 12.3 MILLION VERSUS EUR 3.5 MILLION YEAR AGO.NET LOSS IN FIRST NINE MONTHS OF 2017 WAS €7.8 MILLION COMPARED TO NET LOSS OF €46.5 MILLION YEAR AGO.FULL YEAR OUTLOOK LEADS TO UPWARD REVISION OF EBITDA GUIDANCE .INCREASES ITS FULL YEAR EBITDA GUIDANCE TO €10M - €13 MILLION COMPARED TO PREVIOUS GUIDANCE OF €5 - €10 MILLION‍​.  Full Article

Valneva signs contract with US government
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - VALNEVA SE ::ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT.NEW AGREEMENT WILL SUPPLEMENT INITIAL CONTRACT VALNEVA SIGNED WITH THE US MILITARY IN MARCH 2016.VALNEVA WILL SUPPLY IXIARO DOSES OVER A ONE-YEAR PERIOD FOR A VALUE OF $28.2 MLN GUARANTEED AND UP TO $39.6 MLN.FIRST DELIVERIES ARE EXPECTED TO COMMENCE IN THE COMING WEEKS.  Full Article

French and Benelux stocks-Factors to watch on Sept 27

Sept 27 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.